Radioactive iodine ( 131I) therapy for differentiated thyroid cancer in Japan: Current issues with historical review and future perspective

Annals of Nuclear Medicine

Volumn 26, Issue 2, 2012, Pages 99-112

  Higashi, Tatsuya ^a   Kudo, Takashi ^b   Kinuya, Seigo ^c  

^a Research Institute   (Japan)

^b NAGASAKI UNIVERSITY   (Japan)

^c KANAZAWA UNIVERSITY   (Japan)

Author keywords

Differentiated thyroid cancer; Fukushima; Radioactive iodine; Radioactive iodine therapy; Radiophobia

Indexed keywords

IODINE 131; RADIOACTIVE IODINE;

AGE DISTRIBUTION; ATOMIC BOMB; CANCER CENTER; CULTURAL FACTOR; DIFFERENTIATED THYROID CANCER; DISTANT METASTASIS; GRAVES DISEASE; HEALTH CARE POLICY; HISTORY; HOSPITAL ADMISSION; HOSPITAL BED UTILIZATION; HOSPITALIZATION; HUMAN; JAPAN; MEDICAL SOCIETY; MOLECULARLY TARGETED THERAPY; NATURAL DISASTER; PATIENT ATTITUDE; PATIENT SAFETY; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION DOSE; RADIOACTIVE CONTAMINATION; RADIOISOTOPE THERAPY; REVIEW; SOCIOECONOMICS; THYROIDECTOMY; FEAR; LEGAL ASPECT; NUCLEAR ACCIDENT; NUCLEAR MEDICINE; PSYCHOLOGICAL ASPECT; THYROID TUMOR;

FEAR; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; IODINE RADIOISOTOPES; JAPAN; NUCLEAR MEDICINE; NUCLEAR WEAPONS; RADIOACTIVE HAZARD RELEASE; THYROID NEOPLASMS;

EID: 84858702388     PISSN: 09147187     EISSN: 18646433     Source Type: Journal    
DOI: 10.1007/s12149-011-0553-4     Document Type: Review

References (56)

1. Schlumberger M, Pacini FM. Thyroid tumors. 3rd ed. Paris: Editions Nucleon; 2006.
2. Okamoto T. Radioactive iodine treatment for differentiated thyroid carcinoma in Japan. Surgery. 2010;147:432-3.
3. Radiation Effects Research Foundation. http://www.rerf.jp/general/qa-e/ qa1.html.
4. NHK (Japan Broadcasting Corporation) Hiroshima Broadcast Station. "Hadashi-no-Gen ha Owaranai. Maboroshi-no Zokuhenkarano Messeji. (Barefoot Gen was supposed to continue. Message from an unfinished sequal.)" Japanese TV program, broadcasted on July 30, 2010. Japanese. http://www.nhk.or.jp/ hiroshima/furusato/kako/100730-sp.html.
5. Hiroshi Matsubara. "Prejudice haunts atomic bomb survivors. Hibakusha often hesitant to claim benefits for fear of social discrimination". Article in The Japan Times. Published on May 8, 2001. http://search.japantimes.co.jp/cgi-bin/nn20010508m1.html.
6. Vardaman JM. Contemporary Japanese History: since 1945. Tokyo: IBC Publishing; 2006. ISBN 978-4-89684-389-7.
7. The Database of Newspapers and Magazines Published during the Post-war Occupation Period from 1945-1949. http://m20thdb.jp/ (Japanese).
8. Masuji I. Kuroi Ame ("Black Rain"). Translated by John Bester. 1st US edition. Tokyo: Kodansha International; 1966. ISBN 0-87011-364-X.
9. Studs T. The Good War. New York: Random House; 1984. p. 542. ISBN 0-394-53103-5.
10. Nakazawa M. Hibakusha-no Kokoro-no Kizu-wo Otte. (Mental trauma of Hibakusha.) Tokyo: Iwanami Shoten Publishers; 2007. ISBN 978-4-00-001941-5 (Japanese).
11. Trumbull R. Nine who survived Hiroshima and Nagasaki. Tokyo: Charles E. Tuttle Company; 1957. ISDN n/a.
12. Trumbull R. Kinoko-gumo ni Owarete (nine who survived Hiroshima and Nagasaki). Translated by Chiyoko Yoshii, Japanese Text. Tokyo: Asunaro Shobo Company; 2010. ISBN 978-4-7515-2216-5 NDC936.
13. History and Organization of Japan Radioisotpe Association. http://www.jrias.or.jp/index.cfm/11,html.
14. Kinoshita F. On the clinical studies of thyroid gland by radioactive iodine I-131. I. Diagnostic use of radioactive iodine I-131 for thyroid disease. Nihon Ketsueki Gakkai Zasshi. 1968;31(5):825-31.
15. Japanese Law Translation. Ministry of Justice, Japan. Pharmaceutical Affairs Act. http://www.japaneselawtranslation.go.jp/law/detail/?id=1789&vm= &re=02.
16. Top page of the Japanese Society of Nuclear Medicine Homepage. http://www.jsnm.org/english/overview.
17. Hoshino T. Etiologic role of ionizing radiation on the development of leukemia: clinical and statistical studies on leukemia in patients treated with radioiodine and in atomic bomb survivors. Acta Haem Jpn. 1968;31:825-31.
18. Saenger EL, Thoma GE, Tompkins EA. Incidence of leukemia following treatment of hyperthyroidism. Preliminary report of the Cooperative Thyrotoxicosis Therapy Follow-up Study. JAMA. 1968;205:855-62.
19. Graham GD, Burman KD. Radioiodine treatment of Graves'disease. An assessment of its potential risks. Ann Intern Med. 1986;105:900-5. (Pubitemid 17201771)
20. Ron E, Doody MM, Becker DV, Brill AB, Curtis RE, Goldman MB, et al. Cancer mortality following treatment for adult hyperthyroidism. Cooperative Thyrotoxicosis Therapy Follow-up Study. JAMA. 1998;280:347-55.
21. History of the World Federation of Nuclear Medicine and Biology. http://www.wfnmb.org/article/history-18.
22. International Basic Standards for Protection against Ionizing Radiation and for the Safety of Radiation Sources (Safety Series) International Atomic Energy Agency, Vienna, Austria; 1996.
23. ICRP Publication 73. Radiological protection and safety in medicine. Ann ICRP. 1996;26(2).
24. ICRP Publication-94. Release of patients after therapy with unsealed radionuclides. Ann ICRP. 2004;34(2).
25. Goldsmith SJ. The real cost of theoretic risk avoidance: the need to challenge unsubstantiated concerns about 131I therapy. J Nucl Med. 2011;52(5):681-2.
26. Subcommittee for Thyroid Radioiodine Therapy of the Japanese Society of Nuclear Medicine in Oncology and Immunology and the Japanese Society of Nuclear Medicine. Koujousen-no Houshasei-Youdo-Naiyouryouhou -nikansuru Gaidorain. (Management guidelines for patients with thyroid cancer.) http://oncology.jsnm. org/files/pdf/thyroid-guideline09.pdf (Japanese).
27. Subcommittee for Thyroid Radioiodine Therapy of the Japanese Society of Nuclear Medicine in Oncology and Immunology and the Japanese Society of Nuclear Medicine. Basedou-Byou-no Houshasei-Youdo-Naiyouryouhou -nikansuru Gaidorain. (Management guidelines for patients with Graves' Disease.) http://oncology.jsnm. org/files/pdf/pasedo-guideline09.pdf (Japanese).
28. Mori Y, Kusakabe K, Ikekubo K, Ishikawa N, Nakada K, Kanaya S, et al. Guide-line of the radio-iodine (131I) therapy in Graves'disease and thyroid cancer. Kaku Igaku. 2005;42(2):17-32. (Japanese). (Pubitemid 40489061)
29. Udelsmann R, Shaha AR. Is total thyroidectomy the best possible surgical management for well-differentiated thyroid cancer? Lancet Oncol. 2005;6(7):529-31. (Pubitemid 40903634)
30. Mazzaferri EL, Jhiang SM. Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med. 1994;97:419-28.
31. Watkinson JC. British Thyroid Association. The British Thyroid Association guidelines for the management of thyroid cancer in adults. Nucl Med Commun. 2004;25:897-900. (Pubitemid 39180281)
32. Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, et al. American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid Cancer. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2009;19:1167-214.
33. Bilimoria KY, Bentrem DJ, Ko CY, Stewart AK, Winchester DP, Talamonti MS, et al. Extent of surgery affects survival for papillary thyroid cancer. Ann Surg. 2007;246:375-81. (Pubitemid 47312122)
34. National Comprehensive Cancer Network (2010) NCCN clinical practice guidelines in oncology. Thyroid carcinoma, vol. 1. http://www.nccn.org/ professionals/physician-gls/PDF/thyroid/pdf.
35. Shigematsu N, Takami H, Ito N, Kubo A. Nationwide survey on the treatment policy for well-differentiated thyroid cancer - results of a questionnaire distributed at the 37th meeting of the Japanese Society of Thyroid Surgery. Endocr J. 2005;52:429-91.
36. Shigematsu N, Takami H, Kubo A. Unique treatment policy for well-differentiated thyroid cancer in Japan: results of a questionnaire distributed to members of the Japanese Society of Thyroid Surgery and the International Association of Endocrine Surgeons. Endocr J. 2006;53:829-39. (Pubitemid 46045130)
37. Lee YS, Nam KH, Chung WY, Chang HS, Shigematsu N, Takami H, et al. Practical management of well differentiated thyroid carcinoma in Korea. Endocr J. 2008;55(6):1015-24.
38. Takami HE. Current status of molecularly targeted drugs for the treatment of advanced thyroid cancer (review). Endocr J. 2011;58(3):151-3. (Epub 2011 Mar 4).
39. Takami H, Ito Y, Okamoto T, Yoshida A. Therapeutic strategy for differentiated thyroid carcinoma in Japan based on a newly established guideline managed by Japanese Society of Thyroid Surgeons and Japanese Association of Endocrine Surgeons. World J Surg. 2011;35:111-21.
40. Sugitani I, Kasai N, Fujimoto Y, Yanagisawa A. A novel classification system for patients with PTC: addition of the new variables of large (3 cm or greater) nodal metastases and reclassification during follow-up period. Surgery. 2004;135:139-48. (Pubitemid 38130764)
41. Japan Association of Endocrine Surgeons and Japan Association of Thyroid Surgery. Koujousen Shuyou Shinryo Gaidorain (Management guidelines for patients with thyroid nodules and differentiated thyroid cancer 2010.) Tokyo: Kanehara & Co., Ltd.; 2010. ISBN:978-4-307-20283-1 (Japanese).
42. Koizumi K, Kusakabe K, Okamoto T, Kanaya S, Kanaya K, Ito K, Subcommittee for Thyroid Radioiodine Therapy; The Japanese Society of Nuclear Medicine in Oncology and Immunology and the Japanese Society of Nuclear Medicine, et al. Koujousenngann-no Houshasei-Yodo-Naiyouryouhou-niokeru RI Chiryobyoushitu Kadoujoukyo-no Jittaichousa-Houkoku (Dai-2-hou) [The second surveillance report on the actual operational status of medical ward environment for radioactive iodine therapy of differentiated thyroid cancers in Japan (the second survey in 2010)]. Kaku Igaku. 2011;48(1):15-7. (Japanese).
43. Bai CS, Kumar A, Pant GS. Radioiodine dose for remnant ablation in differentiated thyroid carcinoma: a randomized clinical trial in 509 patients. J Clin Endocrinol Metab. 2004;89:1666-73. (Pubitemid 38507919)
44. Hackshaw A, Harmer C, Mallick U, Haq M, Franklyn JA. I-131 activity for remnant ablation in patients with differentiated thyroid cancer: a systematic review. J Clin Endocrinol Metab. 2007;92:28-38. (Pubitemid 46075005)
45. Higashi T, Nishii R, Yamada S, Nakamoto Y, Ishizu K, Kawase S, et al. Delayed initial radioactive iodine therapy resulted in poor survival in patients with metastatic differentiated thyroid carcinoma: a retrospective statistical analysis of 198 cases. J Nucl Med. 2011;52:683-9.
46. Practical Guideline for I-131 remnant ablation in patients with differentiated thyroid cancer as out-patient therapy. (I-131 Gairai-Ablation-Jisshi-Youkou). http://oncology.jsnm.org/i-131/2010/05-28 (Japanese).
47. Konishi J, Tamaki N, Nakada K, Kusakabe K, Maki M, Kanbe M, et al. Assessment of the efficacy, safety and pharmacokinetics of SKG-02 (recombinant human TSH) in postoperative diagnosis if well-differentiated thyroid cancer - a Japanese prospective, controlled, multicenter open label study. Kaku Igaku. 2010;47(4):479-96. (Japanese).
48. Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, et al. Effect of axitinib (AG-013736) on fatigue, thyroidstimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci. 2010;101(4):963-8. (Epub 2009 Dec 9).
49. Pacini F, Schlumberger M, Dralle H, Elisei R, Smit JW, Wiersinga W. European Thyroid Cancer Taskforce. European consensus for the management of patients with differentiated thyroid carcinoma of the follicular epithelium. Eur J Endocrinol. 2006;154(6):787-803. (Pubitemid 43997716)
50. Yamaguchi T, Shinkai T, Sugawara S, Yoshimura K, Hosokawa Y, Moriyama Y, et al. Evaluation of social adaptation of cancer patients. Report Collection of Research Projects supported by Grant-in-aid for Cancer Research of Ministry of Health, Labour and Welfare. 2002;180-182. ISSN 1346-9169.
51. Watanabe N, Sato H, Kawahara H, Sasaki Y. Utilization of radionuclide therapy facility and assembly-temporary type therapeutic facility for medical treatment of radioactivity contaminated patients in nuclear emergency. Kaku Igaku. 2011;48(2):121-37. (Japanese).
52. Countermeasures for the Great East Japan Earthquake. National Police Agency. http://www.npa.go.jp/archive/keibi/biki/index-e.htm.
53. IAEA Fukushima Nuclear Accident Update Log-Updates of 12 April 2011. Iaea.org. Retrieved 24 April 2011. http://www.iaea.org/newscenter/news/ tsunamiupdate01.html.
54. Homepage of the Japanese Society of Nuclear Medicine http://www.jsnm.org/ english/overview ICRP Publication 111. Ann ICRP. 2009;39. ISSN 0146-6453.
55. ICRP Publication 111. Application of the commission's recommendations to the protection of people living in long-term contaminated areas after a nuclear accident or a radiation emergency. Ann ICRP. 2009;39(3).
56. The Japanese Society of Nuclear Medicine. Advances of 50 Annual Meetings of the Japanese Society of Nuclear Medicine ("Nihon-Kakuigakkai-gakujutsu- Soukai. Gojukkai-no-Ayumi"); 2010 (Japanese).